Tendency of spherically imploding plasma liners formed by merging plasma jets to evolve toward spherical symmetry

Three dimensional hydrodynamic simulations have been performed using smoothed particle hydrodynamics (SPH) in order to study the effects of discrete jets on the processes of plasma liner formation, implosion on vacuum, and expansion. The pressure history of the inner portion of the liner was qualitatively and quantitatively similar from peak compression through the complete stagnation of the liner among simulation results from two one dimensional radiationhydrodynamic codes, 3D SPH with a uniform liner, and 3D SPH with 30 discrete plasma jets. Two dimensional slices of the pressure show that the discrete jet SPH case evolves towards a profile that is almost indistinguishable from the SPH case with a uniform liner, showing that non-uniformities due to discrete jets are smeared out by late stages of the implosion. Liner formation and implosion on vacuum was also shown to be robust to Rayleigh-Taylor instability growth. Interparticle mixing for a liner imploding on vacuum was investigated. The mixing rate was very small until after peak compression for the 30 jet simulation.Comment: 28 pages, 16 figures, submitted to Physics of Plasmas (2012

One-dimensional radiation-hydrodynamic scaling studies of imploding spherical plasma liners

One-dimensional radiation-hydrodynamic simulations are performed to develop insight into the scaling of stagnation pressure with initial conditions of an imploding spherical plasma shell or "liner." Simulations reveal the evolution of high-Mach-number (M), annular, spherical plasma flows during convergence, stagnation, shock formation, and disassembly, and indicate that cm- and {\mu}s-scale plasmas with peak pressures near 1 Mbar can be generated by liners with initial kinetic energy of several hundred kilo-joules. It is shown that radiation transport and thermal conduction must be included to avoid non-physical plasma temperatures at the origin which artificially limit liner convergence and thus the peak stagnation pressure. Scalings of the stagnated plasma lifetime ({\tau}stag) and average stagnation pressure (Pstag, the pressure at the origin, averaged over {\tau}stag) are determined by evaluating a wide range of liner initial conditions. For high-M flows, {\tau}stag L0/v0, where L0 and v0 are the initial liner thickness and velocity, respectively. Furthermore, for argon liners, Pstag scales approximately as v0^(15/4) over a wide range of initial densities (n0), and as n0^(1/2) over a wide range of v0. The approximate scaling Pstag ~ M 3/2 is also found for a wide range of liner-plasma initial conditions.Comment: 28 pages, 12 figures, accepted by Physics of Plasmas (June 23, 2011

Novel Methodology for Creating Macaque Retinas with Sortable Photoreceptors and Ganglion Cells

Purpose: The ability to generate macaque retinas with sortable cell populations would be of great benefit to both basic and translational studies of the primate retina. The purpose of our study was therefore to develop methods to achieve this goal by selectively labeling, in life, photoreceptors (PRs) and retinal ganglion cells (RGCs) with separate fluorescent markers. Methods: Labeling of macaque (Macaca fascicularis) PRs and RGCs was accomplished by subretinal delivery of AAV5-hGRK1-GFP, and retrograde transport of micro-ruby™ from the lateral geniculate nucleus, respectively. Retinas were anatomically separated into different regions. Dissociation conditions were optimized, and cells from each region underwent fluorescent activated cell sorting (FACS). Expression of retinal cell type- specific genes was assessed by quantitative real-time PCR to characterize isolated cell populations. Results: We show that macaque PRs and RGCs can be simultaneously labeled in-life and enriched populations isolated by FACS. Recovery from different retinal regions indicated efficient isolation/enrichment for PRs and RGCs, with the macula being particularly amendable to this technique. Conclusions: The methods and materials presented here allow for the identification of novel reagents designed to target retinal ganglion cells and/or photoreceptors in a species that is phylogenetically and anatomically similar to human. These techniques will enable screening of intravitreally- delivered AAV capsid libraries for variants with increased tropism for PRs and/or RGCs and the evaluation of vector tropism and/or cellular promoter activity of gene therapy vectors in a clinically relevant species

Quantitative imaging of coronary blood flow

Positron emission tomography (PET) is a nuclear medicine imaging modality based on the administration of a positron-emitting radiotracer, the imaging of the distribution and kinetics of the tracer, and the interpretation of the physiological events and their meaning with respect to health and disease. PET imaging was introduced in the 1970s and numerous advances in radiotracers and detection systems have enabled this modality to address a wide variety of clinical tasks, such as the detection of cancer, staging of Alzheimer's disease, and assessment of coronary artery disease (CAD). This review provides a description of the logic and the logistics of the processes required for PET imaging and a discussion of its use in guiding the treatment of CAD. Finally, we outline prospects and limitations of nanoparticles as agents for PET imaging

Triple-gated motion and blood pool clearance corrections improve reproducibility of coronary 18F-NaF PET

PurposeTo improve the test-retest reproducibility of coronary plaque 18F-sodium fluoride (18F-NaF) positron emission tomography (PET) uptake measurements.MethodsWe recruited 20 patients with coronary artery disease who underwent repeated hybrid PET/CT angiography (CTA) imaging within 3 weeks. All patients had 30-min PET acquisition and CTA during a single imaging session. Five PET image-sets with progressive motion correction were reconstructed: (i) a static dataset (no-MC), (ii) end-diastolic PET (standard), (iii) cardiac motion corrected (MC), (iv) combined cardiac and gross patient motion corrected (2 × MC) and, (v) cardiorespiratory and gross patient motion corrected (3 × MC). In addition to motion correction, all datasets were corrected for variations in the background activities which are introduced by variations in the injection-to-scan delays (background blood pool clearance correction, BC). Test-retest reproducibility of PET target-to-background ratio (TBR) was assessed by Bland-Altman analysis and coefficient of reproducibility.ResultsA total of 47 unique coronary lesions were identified on CTA. Motion correction in combination with BC improved the PET TBR test-retest reproducibility for all lesions (coefficient of reproducibility: standard = 0.437, no-MC = 0.345 (27% improvement), standard + BC = 0.365 (20% improvement), no-MC + BC = 0.341 (27% improvement), MC + BC = 0.288 (52% improvement), 2 × MC + BC = 0.278 (57% improvement) and 3 × C + BC = 0.254 (72% improvement), all p < 0.001). Importantly, in a sub-analysis of 18F-NaF-avid lesions with gross patient motion > 10 mm following corrections, reproducibility was improved by 133% (coefficient of reproducibility: standard = 0.745, 3 × MC = 0.320).ConclusionJoint corrections for cardiac, respiratory, and gross patient motion in combination with background blood pool corrections markedly improve test-retest reproducibility of coronary 18F-NaF PET

Conditioning with Treosulfan and Fludarabine followed by Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies

In this prospective study 60 patients of median age 46 (range: 5-60 years), with acute myelogenous leukemia (AML; n = 44), acute lymphoblastic leukemia (ALL; n = 3), or myelodysplastic syndrome (MDS; n = 13) were conditioned for allogeneic hematopoietic cell transplantation with a treosulfan/fludarabine (Flu) combination. Most patients were considered at high risk for relapse or nonrelapse mortality (NRM). Patients received intravenous treosulfan, 12 g/m2/day (n = 5) or 14 g/m2/day (n = 55) on days −6 to −4, and Flu (30 mg/m2/day) on days −6 to −2, followed by infusion of marrow (n = 7) or peripheral blood stem cells (n = 53) from HLA-identical siblings (n = 30) or unrelated donors (n = 30). All patients engrafted. NRM was 5% at day 100, and 8% at 2 years. With a median follow-up of 22 months, the 2-year relapse-free survival (RFS) for all patients was 58% and 88% for patients without high-risk cytogenetics. The 2-year cumulative incidence of relapse was 33% (15% for patients with MDS, 34% for AML in first remission, 50% for AML or ALL beyond first remission and 63% for AML in refractory relapse). Thus, a treosulfan/Flu regimen was well tolerated and yielded encouraging survival and disease control with minimal NRM. Further trials are warranted to compare treosulfan/Flu to other widely used regimens, and to study the impact of using this regimen in more narrowly defined groups of patients